PSMD9: A Potential Drug Target and Biomarker for 26S Proteasome Non-ATPase Regulatory Subunit 9

Target Name: PSMD9

NCBI ID: G5715

PSMD9

PSMD9: A Potential Drug Target and Biomarker for 26S Proteasome Non-ATPase Regulatory Subunit 9

Proteasomes are a type of protein-protein interaction module that play a crucial role in regulating protein synthesis in eukaryotic cells. The 26S proteasome is one of the two major types of proteasomes found in eukaryotic cells, and it is involved in the processing of polyproteins from precursors. The non-ATPase regulatory subunit 9 (PSMD9) is a key protein that functions as a negative regulator of the 26S proteasome. In this article, we will discuss PSMD9 as a potential drug target and biomarker in various diseases.

PSMD9: Structure and Function

PSMD9 is a 23 kDa protein that is composed of 115 amino acid residues. It has a characteristic Rossmann-fold structure that is similar to other proteins involved in protein-protein interactions. PSMD9 is primarily localized to the endoplasmic reticulum (ER) and is involved in regulating the processing of polyproteins by the 26S proteasome.

PSMD9 functions as a negative regulator of the 26S proteasome by preventing the assembly of 26S particles. It does this by interacting with the alpha-helices of the 26S proteasome subunit B (26SB) and obstructing the formation of the active 26S particle. As a result, PSMD9 indirectly promotes the processing of polyproteins by the 26S proteasome.

PSMD9 is also involved in regulating the activity of the 26S proteasome by interacting with the regulatory subunit A (26S-A) of the 26S proteasome. 26S-A is a protein that functions as a scaffold to recruit other regulatory subunits to the 26S proteasome. By interacting with PSMD9, 26S-A can modulate the activity of the 26S proteasome, including its processing of polyproteins.

PSMD9 is a potential drug target because of its involvement in the regulation of the 26S proteasome. The 26S proteasome is involved in the production of a wide variety of proteins that are involved in various cellular processes, including cell signaling, tissue repair, and intracellular transport. Therefore, inhibiting the activity of the 26S proteasome has the potential to be a useful therapeutic approach for a variety of diseases.

PSMD9 is also a potential biomarker for certain diseases. The 26S proteasome is a key regulator of protein synthesis in eukaryotic cells, and changes in its activity can be indicative of certain diseases. For example, alterations in the 26S proteasome activity have been observed in a variety of diseases, including cancer, neurodegenerative diseases, and neuroinflammatory diseases. Therefore, measuring the activity of the 26S proteasome using PSMD9 could be a useful biomarker for these diseases.

PSMD9 Interactions with Other Proteins

PSMD9 has several interactions with other proteins that are involved in the regulation of the 26S proteasome. One of the most significant interactions is with the regulatory subunit A (26S-A) of the 26S proteasome. As mentioned earlier, 26S-A is a protein that functions as a scaffold to recruit other regulatory subunits to the 26S proteasome. By interacting with PSMD9, 26S-A can modulate the activity of the 26S proteasome, including its processing of polyproteins.

PSMD9 also interacts with the protein

Protein Name: Proteasome 26S Subunit, Non-ATPase 9

Functions: Acts as a chaperone during the assembly of the 26S proteasome, specifically of the base subcomplex of the PA700/19S regulatory complex (RC). During the base subcomplex assembly is part of an intermediate PSMD9:PSMC6:PSMC3 module, also known as modulator trimer complex; PSMD9 is released during the further base assembly process

The "PSMD9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMD9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets